Astria Therapeutics (ATXS) EBT: 2013-2018
Historic EBT for Astria Therapeutics (ATXS) over the last 6 years, with Dec 2018 value amounting to -$26.0 million.
- Astria Therapeutics' EBT fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- Latest data reveals that Astria Therapeutics reported EBT of -$26.0 million as of FY2018, which was up 4.93% from -$27.4 million recorded in FY2017.
- In the past 5 years, Astria Therapeutics' EBT ranged from a high of -$21.9 million in FY2014 and a low of -$36.2 million during FY2016.
- Its 3-year average for EBT is -$29.9 million, with a median of -$27.4 million in 2017.
- Per our database at Business Quant, Astria Therapeutics' EBT slumped by 49.12% in 2015 and then climbed by 24.22% in 2017.
- Astria Therapeutics' EBT (Yearly) stood at -$21.9 million in 2014, then slumped by 49.12% to -$32.6 million in 2015, then declined by 10.77% to -$36.2 million in 2016, then rose by 24.22% to -$27.4 million in 2017, then increased by 4.93% to -$26.0 million in 2018.